Isotope Technologies Garching GmbH announces in-licensing of DOTA-Zoledronate for Bone Targeted Radionuclide Theranostics of Osseous Metastases

Garching (ots) - The ITM Group announced today that its subsidiary
ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next
generation theranostic agent for Bone Targeted Radionuclide Therapy
and Diagnostics in patients suffering from bone metastases.
DOTA-Zoledronate specifically targets cancerous bone lesions and,
when radiolabeled with therapeutic or diagnostic radioisotopes, has
shown high potential for PET-Imaging and Endoradiotherapy. Due to its
versatile properties for radiolabeling, DOTA-Zoledronate is a
promising agent for the development of other future-oriented
radionuclide therapy concepts for personalized nuclear oncology.
Fundamental research into radiolabeled DOTA-Zoledronate conjugates
has recently been conducted at the Johannes Gutenberg University
Mainz led by the head of the Institute of Nuclear Chemistry, Prof.
Frank Rösch.

About DOTA-Zoledronate

DOTA-Zoledronate is a DOTA-conjugated bisphosphonic acid indicated
for the treatment of bone metastases in patients with serious cancers
such as prostate or breast cancer. Its affinity for hydroxyapatite
which is a major component of the mineral matrix of the bone makes it
preferable for Bone Targeted Radionuclide Imaging and Therapy. In
first studies DOTA-Zoledronate showed an outstanding target to
background ratio and a fast clearance pathway. Moreover, the novel
bone agent is attractive for tagging of various radionuclides like
the generator derived PET-radionuclide Gallium-68, therapeutic
beta-emitting no-carrier-added (n.c.a) Lutetium-177 as well as the
?-particle emitters Actinium-225 and Bismuth-213.

About therapeutic n.c.a. Lutetium-177

ITM Group's lead product, n.c.a. Lutetium-177, is a superior
therapeutic radionuclide currently undergoing Marketing Authorization
procedure. Upon approval by the European Medicines Agency (EMA),
which is expected in Q1 2016, the medicinal product will be launched
under the brand name EndolucinBeta.

About Bone Metastases

Certain cancers such as breast, prostate, lung, thyroid, and
kidney cancers are prone to spread to the bone. In breast and
prostate cancer patients in particular, the bone is often the first
distant site of cancer spread with more than 2 out of 3 patients
developing this secondary disease in the late stage resulting in more
than 1.5 Million cases of secondary cancer in bone worldwide.
Metastatic spread of the cancer into the bones causes severe bone
pain, spinal cord compression and even skeletal fractures thereby
tremendously reducing patients' quality of life.

About the ITM Group

The ITM Group is a privately held group of radiopharmaceutical
companies dedicated to the development and proprietary production of
novel radiopharmaceuticals and radiomedical devices. Today, more than
50 highly trained employees bring in their profound knowledge and
experience of meanwhile more than a decade, focusing on next
generation radioisotope sourcing and processing for the treatment of
numerous serious oncological diseases. The company's main goal is to
improve the wellbeing and quality of life of patients by bringing a
new generation of targeted radiopharmaceuticals for theranostics to
the market.

Contact:
Konstantin Zhernosekov
Head of Product Management & Marketing
Phone: +49 89 3298986-32
Mail: Konstantin.Zhernosekov@itg-garching.de

Steffen Schuster
Chief Executive Officer (CEO)
Phone: +49 89 3298986-22
Mail: Steffen.Schuster@itm.ag

ITM Isotopen Technologien München AG
Aufsichtsratsvorsitzender - Udo J. Vetter, Vorstandsvorsitzender -
Steffen Schuster, Sitz der Gesellschaft - Lichtenbergstr. 1, 85748
Garching - HG München - HRB 154944